Palleon Pharmaceuticals

Leading biotechnology company .

Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer. Despite the dramatic success of first-generation immuno-oncology agents, most patients still do not respond to these treatments. It is now recognized that cancers use multiple pathways to evade the immune system in the tumor microenvironment, suppressing a full range of innate immune cells such as dendritic cells, macrophages, and NK Cells, as well as adaptive immune cells, mainly T cells. A novel approach is needed to overcome this broad suppression of the human immune system.